Regorafenib Hydrochloride

• CAT Number: I005013
• CAS Number: 835621-07-3
• Molecular Formula: C21H16Cl2F4N4O3
• Molecular Weight: 519.28
• Purity: ≥95%
• Synonyms: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide hydrochloride
• Target: Autophagy
• Solubility: DMSO: ≥ 5.6 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrochloride
• InChI: InChI=1S/C21H15ClF4N4O3.ClH/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26;/h2-10H,1H3,(H,27,31)(H2,29,30,32);1H
• InChIKey: ACSWJKPZXNIVMY-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.Cl

Regorafenib hydrochloride（Cat No.:I005013）is a multi-kinase inhibitor that targets various kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment, including VEGFR, PDGFR, RAF, and KIT. By inhibiting these pathways, regorafenib disrupts tumor growth, metastasis, and blood vessel formation. It is used primarily in the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. Regorafenib’s broad activity against multiple cancer-related kinases makes it a valuable agent in oncology research, particularly for patients with advanced, treatment-resistant cancers, offering potential for more targeted cancer therapies.

Reference

[1]. Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.
[2]. Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2(1), 39-49.
[3]. Carr BI, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228(2), 292-297.